Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 2/20 | 0.50 |
| ▸ | NR1H4 | Q96RI1 | 6/20 | 0.42 |
| ▸ | TTR | P02766 | 4/20 | 0.42 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KMO | O15229 | 1/20 | 0.40 |
| ▸ | HTR5A | P47898 | 1/20 | 0.39 |
| ▸ | F9 | P00740 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9907373 | 0.91 | HTR5A (0.50) | PLAUTTRPLA2G2DKMOHTR5A | |
| SCHEMBL9907382 | 0.85 | PLAU (0.47) | PLAUTTRPLA2G2DAURKATSHR | |
| SCHEMBL9907365 | 0.84 | TP53 (0.47) | NR1H4 | |
| SCHEMBL9907693 | 0.83 | PLAU (0.50) | PLAUTTRPLA2G2DAURKAHTR5A | |
| SCHEMBL9907911 | 0.82 | HTR5A (0.60) | PLAUHTR5A | |
| SCHEMBL9907335 | 0.80 | PLAU (0.55) | PLAUPLA2G2DKMOGRIN2DGRIN2A | |
| SCHEMBL9907383 | 0.78 | KDM4C (0.49) | PLAUTTRKMO | |
| SCHEMBL16502616 | 0.78 | DOT1L (0.45) | PLAUTTRPLA2G2DTRPV1 | |
| SCHEMBL9907318 | 0.78 | PLAU (0.50) | PLAUPLA2G2DKMOHTR5AGRIN2D | |
| SCHEMBL2671644 | 0.77 | PLAU (0.59) | PLAUTTRPLA2G2DTSHRKMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853242-B2 | Nitrogenous-ring acylguanidine derivative | ASTELLAS PHARMA INC. (JP) | 2014-10-07 | — | — | US | disclosed |
| US-8853242-B2 | Nitrogenous-ring acylguanidine derivative | ASTELLAS PHARMA INC. (JP) | 2014-10-07 | — | — | US | disclosed |
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | PLAU 3322/4885NR1H4 310/4885TTR 3634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.